A study for proposal of use of regulatory T cells as a prognostic marker and establishing an optimal threshold level for their expression in chronic lymphocytic leukemia

References

• Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151–1164.
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4 + CD25high regulatory cells in human peripheral blood. J Immunol 2001;167: 1245–1253.
   PubMed Web of Science ®Google Scholar
• Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804–811.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Saxena R. Regulatory T cells: a review. Natl Med J India 2012;25:341–351.
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4 + CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106:2018–2025.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Mahapatra M, Saxena R. Flow cytometric immunophenotyping of regulatory T cells in chronic lymphocytic leukemia: comparative assessment of various markers and use of novel antibody panel with CD127 as alternative to transcription factor FoxP3. Leuk Lymphoma 2013;54:778–789.
   PubMed Web of Science ®Google Scholar
• Ghia P, Ferreri AM, Caligaris-Cappio F. Chronic lymphocytic leukemia. Crit Rev Oncol Hematol 2007;64:234–246.
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Binet J-L, Caligaris-Cappio F, Catovsky D, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006;107:859–861.
   PubMed Web of Science ®Google Scholar
• Scrivener S, Goddard RV, Kaminski ER, et al. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44:383–389.
   PubMed Web of Science ®Google Scholar
• Christopoulos P, Pfeifer D, Bartholomé K, et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 2011; 117:3836–3846.
   PubMed Web of Science ®Google Scholar
• Riley RD, Hayden JA, Steyerberg EW, et al. Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med 2013; 10:e1001380.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009;115:363–372.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023–1029.
   PubMed Web of Science ®Google Scholar
• Schroers R, Griesinger F, Trümper L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005;19:750–758.
   PubMed Web of Science ®Google Scholar
• Nipp RD, Volkheimer AD, Davis ED, et al. CD38 variation as a prognostic factor in chronic lymphocytic leukemia. Leuk Lymphoma 2014;55:191–194.
   PubMed Web of Science ®Google Scholar
• Hus I, Podhorecka M, Bojarska-Junak A, et al. The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 2006;17:683–690.
   PubMed Web of Science ®Google Scholar
• Biancotto A, Dagur PK, Fuchs JC, et al. Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia. Mod Pathol 2012;25:246–259.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Laurenti L, Minervini MM, et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 2011;35:363–368.
   PubMed Web of Science ®Google Scholar
• Deutsch V, Perry C, Polliack A. Expansion of regulatory T cells in B chronic lymphocytic leukemia: enhanced “brakes” on host immunity. Leuk Lymphoma 2009;50:687–688.
   PubMed Web of Science ®Google Scholar
• Jak M, Mous R, Remmerswaal EBM, et al. Enhanced formation and survival of CD4 + CD25hi Foxp3 + T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:788–801.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Schmitt M, Kowal M, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008;20:677–682.
   PubMed Web of Science ®Google Scholar
• Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4 + T reg cells. J Exp Med 2006;203:1701–1711.
   PubMed Web of Science ®Google Scholar
• Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693–1700.
   PubMed Web of Science ®Google Scholar
• Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves. Crit Care 2004;8:508–512.
   PubMed Web of Science ®Google Scholar
• D’Arena G, D’Auria F, Simeon V, et al. A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. Am J Hematol 2012;87:628–631.
   PubMed Web of Science ®Google Scholar
• Weiss L, Melchardt T, Egle A, et al. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 2011;117:2163–2169.
   PubMed Web of Science ®Google Scholar
• Badoual C, Hans S, Fridman WH, et al. Revisiting the prognostic value of regulatory T cells in patients with cancer. J Clin Oncol 2009;27:e5–e6; author reply e7.
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3 + T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186–192.
   PubMed Web of Science ®Google Scholar
• Hemingway H, Croft P, Perel P, et al. Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ 2013;346:e5595.
   PubMedGoogle Scholar
• Steyerberg EW, Moons KGM, van der Windt DA, et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med 2013;10:e1001381.
   PubMed Web of Science ®Google Scholar
• Hingorani AD, Windt DA van der, Riley RD, et al. Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ 2013;346:e5793.
   PubMed Web of Science ®Google Scholar
• Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979–985.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005;93:387–391.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180–1184.
   PubMed Web of Science ®Google Scholar
• Piper KP, Karanth M, McLarnon A, et al. Chronic lymphocytic leukaemia cells drive the global CD4 + T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4 + forkhead box P3 + T cells. Clin Exp Immunol 2011;166:154–163.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Simeon V, D’Auria F, et al. Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander? Am J Blood Res 2013;3:52–57.
   PubMedGoogle Scholar
• Mittal S, Marshall NA, Duncan L, et al. Local and systemic induction of CD4 + CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008;111:5359–5370.
   PubMed Web of Science ®Google Scholar
• Szczepanski MJ, Szajnik M, Czystowska M, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009;15:3325–3332.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Rossi G, Minervini MM, et al. Circulating regulatory T cells in “clinical” monoclonal B-cell lymphocytosis. Int J Immunopathol Pharmacol 2011;24:915–923.
   PubMed Web of Science ®Google Scholar
• Nizar S, Copier J, Meyer B, et al. T-regulatory cell modulation: the future of cancer immunotherapy? Br J Cancer 2009;100: 1697–1703.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Deaglio S, Laurenti L, et al. Targeting regulatory T cells for anticancer therapy. Mini Rev Med Chem 2011;11:480–485.
   PubMed Web of Science ®Google Scholar
• Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007;7:880–887.
   PubMed Web of Science ®Google Scholar
• Zhou L, Chong MMW, Littman DR. Plasticity of CD4 + T cell lineage differentiation. Immunity 2009;30:646–655.
   PubMed Web of Science ®Google Scholar
• McClymont SA, Putnam AL, Lee MR, et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 2011;186:3918–3926.
   PubMed Web of Science ®Google Scholar
• Johnston JB. Jump-starting the T cells in CLL. Blood 2013;121: 4016–4017.
   PubMed Web of Science ®Google Scholar
• Stamatopoulos B, Meuleman N, De Bruyn C, et al. A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients. PLoS One 2010; 5: pii: e12780.
   PubMed Web of Science ®Google Scholar